Technology

Publications

OncoSec’s scientists and researchers from collaborating organizations have published several scientific articles regarding intratumoral immunotherapies and electroporation DNA delivery in peer-reviewed journals.

 

Chen, DS. et. al. “Oncology Meets Immunology: The Cancer-Immunity Cycle.” Immunity. 2013 Jul 25; 39 (1):1–10. DOI: dx.doi.org/10.1016/j.immuni.2013.07.012.

Daud AI, Pierce, RH, et al. “Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma.” J Clin Invest. 2016 Aug 15. DOI:10.1172/JCI87324.

Daud AI, et. al. “Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma.” J Clin Oncol 26:5896-5903. DOI: 10.1200/JCO.2007.15.6794.

Herbst RS, et. al. “Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.” Nature. 2014 Nov27;515(7528): 563–567. DOI: 10.1038/nature14011.

Kerkar SP, et. al. “IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.” J Clin Invest. 2011;121(12):4746–4757. DOI: 10.1172/JCI58814.

Kohrt HE, et. al. “Combination strategies to enhance antitumor ADCC.”Immunotherapy. 2012 May; 4(5): 511–527. DOI: 10.2217/imt.12.38.

Lucas ML, et. al. “IL-12 Plasmid Delivery by in Vivo Electroporation for the Successful Treatment of Established Subcutaneous B16.F10 Melanoma.” Mol Ther. 2002 Jun;5(6):668-75. DOI: 10.1006/mthe.2002.0601.

Marabelle, A. et. al. “Intratumoral Immunization: A New Paradigm for Cancer Therapy.” Clin Cancer Res 2014;20:1747-1756. DOI: 10.1158/1078-0432.CCR-13-2116.

Pardoll DM. “The blockade of immune checkpoints in cancer immunotherapy.” Nat Rev Cancer. 2012 Mar 22;12(4):252-64. DOI: 10.1038/nrc3239.

Pierce RH, et. al. “In-situ tumor vaccination: Bringing the fight to the tumor.” Human Vaccines & Immunotherapeutics. 2015; 11(8): 1901-1909. DOI: 10.1080/21645515.2015.1049779.

Sin J, et. al. “Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2180–188-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-c-dependent manner: application of Trp2180–188peptides.” Cancer Immunol Immunother. 2012;61:1671–1682. DOI: 10.1007/s00262-012-1214-8.

Spranger S, et. al. “Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T-cells.” Sci Transl Med. 2013; 5, 200ra116. DOI: 10.1126/scitranslmed.3006504.

Tumeh PC, et. al. “PD-1 blockade induces responses by inhibiting adaptive immune resistance.” Nature. 2014 Nov 27;515(7528):568-71. DOI: 10.1038/nature13954.